Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

TEAM: Trial of Early Activity and Mobilization (TEAM)

TEAM: An Multi-centre Observational Study of Early Activity and Mobilization in Australia and New Zealand

Patients in the Intensive Care Unit (ICU) traditionally receive bed rest as part of their care. They develop muscle weakness even after only a few days of mechanical ventilation that may prolong their time in ICU and in hospital, but the nature of such weakness is poorly understood.

The weakness that develops in ICU is more substantial than that which would result from bed rest alone and is referred to as ICU acquired weakness (ICUAW). This weakness might be due to the combination of inflammation and immobility. The exact mechanisms leading to the nerve and muscle damage which occurs in critical illness are not yet fully understood and require further investigation. However, it is known that ICUAW has an effect on a patient's ability to breathe without a ventilator, walk and perform simple activities (like washing and toileting) and often results in longer mechanical ventilation time and hence, longer hospital stays than might otherwise be expected. It may also affect a patient's ability to return home after their hospital stay. The recovery period in Australian and New Zealand ICU patients is unknown but a trial from Canada has reported ongoing weakness five years after leaving ICU. Weakness in survivors of intensive care is known to be a substantial problem. It is currently not known whether ICUAW may be avoided or its severity reduced with simple strategies of early exercise in ICU.

There are no data about the level of activity and mobility in critically ill patients in Australian and New Zealand ICUs. These data are urgently required to plan a program of research to test whether increasing the level of mobility and activity in our critically ill patients is safe, feasible and efficacious in terms of reducing the severity of ICUAW and improving patient-centred outcomes. The program of research will first include a study to observe the mobility levels in 25 ICUs across Australia and New Zealand to determine safety, barriers to mobility and what type of activities are undertaken by our patients.

From the observational data we plan to develop a pilot randomised controlled trial of early mobility and activity in intensive care units across Australia and New Zealand. This simple, cost-effective strategy may improve functional ability, decrease time on mechanical ventilation and improve long term outcomes in this patient group. By initiating such a program, ANZ investigators might be able to change future patient outcomes worldwide.

Aperçu de l'étude

Type d'étude

Observationnel

Inscription (Réel)

192

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Victoria
      • Melbourne, Victoria, Australie, 3104
        • The Alfred
      • Wellington, Nouvelle-Zélande
        • Wellington Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Intensive care unit patients

La description

Inclusion Criteria:

  • they have received invasive mechanical ventilation for at least 24 hours, and have been in ICU less than 72 hours
  • the treating clinician expects the patient to still be receiving invasive mechanical ventilation in the ICU the day after tomorrow.

Exclusion Criteria:

  • Age less than 18 years old

    • Patient has a proven or suspected acute primary brain process that is likely to result in global impairment of conscious level or cognition, such as traumatic brain injury, intracranial haemorrhage, stroke, or hypoxic brain injury after cardiac arrest or asphyxiation.
    • Second or subsequent admission to ICU during a single hospital admission
    • Patient does not speak English
    • Patient has proven or suspected primary myopathic or neurological process associated with prolonged weakness, such as Guillain-Barre syndrome
    • Death is deemed imminent and inevitable
    • Inability to walk without assistance prior to the acute illness that is associated with admission to ICU (use of a cane or walker not an exclusion)
    • Cognitive impairment prior to the acute illness that is associated with admission to ICU (refer data dictionary)
    • Any written "Rest In Bed" or non-weight bearing medical order such as may occur with hip fracture, unstable spine or pelvis, pathological fracture

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: Cohorte
  • Perspectives temporelles: Éventuel

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Best level of activity in ICU
Délai: ICU stay (average 7 days)

Highest level of activity (11 point scale) including:

unknown nothing (lying in bed, passive stretches) sitting in bed, active exercises in bed moved to chair (via hoist, slide etc but no standing) sitting over edge of bed standing transferring bed to chair marching on spot (at bedside) walking with assistance of 2 or more people walking with assistance of 1 person walking independently with a gait aid walking independently without a gait aid

ICU stay (average 7 days)
Dosage of the best level of activity
Délai: Intensive care unit stay (average 7 days)
The time spent performing the best level of activity and the number of times it is achieved
Intensive care unit stay (average 7 days)
Time to standing in ICU
Délai: Intensive care stay (average 7 days)
The number of days in ICU before a patient can stand
Intensive care stay (average 7 days)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Best level of activity at hospital discharge
Délai: Hospital stay (median days 14)

Highest level of activity (11 point scale) including:

unknown nothing (lying in bed, passive stretches) sitting in bed, active exercises in bed passively moved to chair (pat slide, hoist but no standing) sitting over edge of bed standing transferring bed to chair marching on spot (at bedside) walking with assistance of 2 or more people walking with assistance of 1 person walking independently with a gait aid walking independently without a gait aid

Hospital stay (median days 14)
Time to first sit out of bed
Délai: ICU stay (average 7 days)
The number of days until the patient can sit out of bed
ICU stay (average 7 days)
Barriers to mobilisation
Délai: Intensive care unit stay (average 7 days)
Factors that may have been a barrier to mobilizing patients in the ICU
Intensive care unit stay (average 7 days)
Mobilization related adverse events
Délai: Intensive care unit stay (average 7 days)
Adverse events that occured during patient mobilization such as an unplanned extubation or a fall to the floor
Intensive care unit stay (average 7 days)
Time to first physiotherapy
Délai: Intensive care unit stay (average 7 days)
The number of days in intensive care before the patient was reviewed by a physiotherapist
Intensive care unit stay (average 7 days)
Mechanical ventilation free days
Délai: 28 days
The number of mechanical ventilation free days to day 28
28 days
Intensive care unit free days
Délai: Day 28
The number of days the patient spent out of ICU to day 28 (if dead = 0)
Day 28
90 day mortality
Délai: 90 days
The mortality at day 90
90 days
Health related quality of life at 6 months
Délai: 6 months
Health related quality of life reported via telephone interview at 6 months using the EuroQoL EQ5D
6 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chaise d'étude: Carol Hodgson, PhD, ANZIC-RC
  • Directeur d'études: Steve Webb, MD, ANZICS CTG
  • Directeur d'études: Rinaldo Bellomo, MD, ANZIC-RC
  • Chercheur principal: Megan Harrold, PhD Candidate, Royal Perth Hospital
  • Chercheur principal: Heidi Buhr, RN, Royal Prince Alfred Hospital, Sydney, Australia
  • Chercheur principal: Manoj Saxena, MD, St George Hospital
  • Chercheur principal: Paul Young, MD, Wellington Hospital
  • Chercheur principal: Oystein Tronstad, PT, Prince Charles Hospital
  • Chercheur principal: Neil Orford, MD, Barwon Health

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 juillet 2012

Achèvement primaire (Réel)

1 mars 2014

Achèvement de l'étude (Réel)

1 mars 2014

Dates d'inscription aux études

Première soumission

14 août 2012

Première soumission répondant aux critères de contrôle qualité

27 août 2012

Première publication (Estimation)

29 août 2012

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

6 mai 2015

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 mai 2015

Dernière vérification

1 mai 2015

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • ICF

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner